Novartis AG vs Rockwell Automation — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Rockwell Automation trades at $466.2 (market cap $51.04B). The key difference: Novartis AG is far larger — about 5.7× Rockwell Automation's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | ROK | |
|---|---|---|
Market Cap | $290.25B | $51.04B |
Sector | Health | Industrials |
52-Week High | $168.62 | $495.08 |
52-Week Low | $113.50 | $328.67 |
Enterprise Value | $330.27B | $54.67B |
Dividend Yield | 3.17% | 1.2% |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →